340B Under Pressure: Inside Pharma's Push for Greater Clarity

In this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to examine the growing stakes surrounding the 340B Drug Pricing Program — and how claims data, rebate models and legal challenges are shaping manufacturers’ response. Mendelsohn explains drugmaker concerns about overlapping discounts, the gaps in claims visibility that make them difficult to identify and the push to verify dispensing before paying a 340B rebate (all three at the heart of industry revenue leakage issues). Throughout the conversation, Mendelsohn considers what it will take to bring greater accountability and predictability to the program while preserving its underlying purpose. 00:53 - The evolution of 340B  03:39 - Understanding program's growth and impact 07:27 - Manufacturer challenges/complexities in compliance 10:43 - 340B's twisting path: Rebate pilots and more15:44 - Pharma as key stakeholder 18:25 - Claims collection hurdles 20:56 - Lilly and industry strategy shifts 23:19 - Assessing the litigation landscape 25:37 - 340B's role in pricing pie, GTN management29:20 - Fueling future debate? The two drivers